Key result
Dexrazoxane cuts HF risk ~68% during anthracycline therapy, alongside cardioprotective benefits from statins and β-blockers.
Why the study?
Do pharmacologic cardioprotective therapies limit anthracycline-induced cardiotoxicity and preserve cardiac function?
Do pharmacologic cardioprotective therapies limit anthracycline-induced cardiotoxicity and preserve cardiac function?
Answers are grounded in this paper and cite their sources.
Supports tailored risk-based cardioprotection guided by biomarkers and imaging; reinforces its promise in limiting anthracycline cardiotoxicity.
Several pharmacologic strategies offer potential benefit in limiting anthracycline-induced cardiotoxicity and preserving cardiac function. Tailored, risk-based approaches that incorporate cardioprotective therapies early in anthracycline treatment-guided by biomarkers and imaging-are most promising. Further large-scale randomised studies are required to establish optimal combinations and confirm long-term benefit.
No takes yet. Share an insight, caveat, or question.
Alotaibi et al. (2026) conducted a review in Patients treated with anthracycline-based chemotherapy including various cancers (breast, lymphoma, hematological malignancies), some with previous anthracycline exposure.
Synapse has enriched 10 related papers. Consider them for comparative context: